News Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash

Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash

disclab_8xmfcv2j October 26, 2025 October 26, 2025News

Novartis will pay Avidity shareholders $72 a share in cash, a premium of 46% to the company’s Friday closing price.